Ownership history in MORGAN STANLEY · 36 quarters on record
This page tracks every 13F SEC filing in which MORGAN STANLEY reported a position in XTL BIOPHARMACEUTICALS LTD (XTLB). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.
| Quarter | Action | Shares | Change | Chg % | % of Fund | Mkt Value | Price (EOQ) |
|---|---|---|---|---|---|---|---|
| 2025 Q4 | REDUCED | 1,740 | -8,271 | -82.6% | 0.00% | $1K | $0.58 |
| 2025 Q3 | REDUCED | 10,011 | -1,000 | -9.1% | 0.00% | $12K | $1.17 |
| 2025 Q2 | REDUCED | 11,011 | -2,240 | -16.9% | 0.00% | $13K | $1.14 |
| 2025 Q1 | REDUCED | 13,251 | -5,100 | -27.8% | 0.00% | $16K | $1.20 |
| 2024 Q4 | REDUCED | 18,351 | -8,100 | -30.6% | 0.00% | $37K | $2.03 |
| 2024 Q3 | REDUCED | 26,451 | -6,700 | -20.2% | 0.00% | $64K | $2.40 |
| 2024 Q2 | REDUCED | 33,151 | -6,020 | -15.4% | 0.00% | $81K | $2.43 |
| 2024 Q1 | REDUCED | 39,171 | -600 | -1.5% | 0.00% | $110K | $2.81 |
| 2023 Q4 | REDUCED | 39,771 | -800 | -2.0% | 0.00% | $40K | $1.01 |
| 2023 Q3 | REDUCED | 40,571 | -600 | -1.5% | 0.00% | $36K | $0.90 |
As of 2025 Q4 — sorted by position size